Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer
Objective To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer (NSCLC). Methods A total of 95 patients with MET 14 exon (METex14) jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group (47 cases) and an observation group (48 cases) through...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2024-03-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/en/article/doi/10.3971/j.issn.1000-8578.2024.23.0909 |
| _version_ | 1797206007658577920 |
|---|---|
| author | ZHONG Cheng ZHANG Yang CHU Ziang QIAN Hong |
| author_facet | ZHONG Cheng ZHANG Yang CHU Ziang QIAN Hong |
| author_sort | ZHONG Cheng |
| collection | DOAJ |
| description | Objective To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer (NSCLC). Methods A total of 95 patients with MET 14 exon (METex14) jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group (47 cases) and an observation group (48 cases) through a random-number table method. The patients in the control group were treated with crizotinib, whereas those in the observation group were treated with savolitinib. The clinical efficacy and incidence of toxic side effects in both groups were evaluated through a chi-square test, and survival was evaluated through Kaplan-Meier survival analysis. Results Compared with control group (31.91% and 70.21%), the objective response rate and disease control rate of the observation group were 52.08% and 87.50%, respectively (P<0.05). According to Kaplan-Meier survival analysis, the overall survival and progression free survival rates in the observation group were higher than those in the control group (Log rank χ2=8.003, 4.528; P=0.005, 0.033). No statistically significant difference in the degree of toxic side effects was found between the groups (P>0.05). Conclusion Savolitinib can improve the efficacy of treatment for stage Ⅲ/Ⅳ METex14 skip mutation NSCLC patients, prolong survival, enhance the tolerance of patients to savolitinib, and facilitate the management of adverse reactions. |
| first_indexed | 2024-04-24T09:00:10Z |
| format | Article |
| id | doaj.art-dd92fad112fc4c2794b1aca52835a7fe |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-04-24T09:00:10Z |
| publishDate | 2024-03-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-dd92fad112fc4c2794b1aca52835a7fe2024-04-16T02:19:41ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782024-03-0151319119410.3971/j.issn.1000-8578.2024.23.090923-0909Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung CancerZHONG Cheng0ZHANG Yang1CHU Ziang2QIAN Hong3Navy Anqing Hospital Cancer Center, Anqing 246004, ChinaNavy Anqing Hospital Cancer Center, Anqing 246004, ChinaNavy Anqing Hospital Cancer Center, Anqing 246004, ChinaNavy Anqing Hospital Cancer Center, Anqing 246004, ChinaObjective To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer (NSCLC). Methods A total of 95 patients with MET 14 exon (METex14) jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group (47 cases) and an observation group (48 cases) through a random-number table method. The patients in the control group were treated with crizotinib, whereas those in the observation group were treated with savolitinib. The clinical efficacy and incidence of toxic side effects in both groups were evaluated through a chi-square test, and survival was evaluated through Kaplan-Meier survival analysis. Results Compared with control group (31.91% and 70.21%), the objective response rate and disease control rate of the observation group were 52.08% and 87.50%, respectively (P<0.05). According to Kaplan-Meier survival analysis, the overall survival and progression free survival rates in the observation group were higher than those in the control group (Log rank χ2=8.003, 4.528; P=0.005, 0.033). No statistically significant difference in the degree of toxic side effects was found between the groups (P>0.05). Conclusion Savolitinib can improve the efficacy of treatment for stage Ⅲ/Ⅳ METex14 skip mutation NSCLC patients, prolong survival, enhance the tolerance of patients to savolitinib, and facilitate the management of adverse reactions.http://www.zlfzyj.com/en/article/doi/10.3971/j.issn.1000-8578.2024.23.0909non-small cell lung cancermesenchymal-epithelial transition factorsavolitinib |
| spellingShingle | ZHONG Cheng ZHANG Yang CHU Ziang QIAN Hong Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer Zhongliu Fangzhi Yanjiu non-small cell lung cancer mesenchymal-epithelial transition factor savolitinib |
| title | Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer |
| title_full | Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer |
| title_fullStr | Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer |
| title_full_unstemmed | Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer |
| title_short | Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer |
| title_sort | therapeutic effect of savolitinib in patients with stage iii iv non small cell lung cancer |
| topic | non-small cell lung cancer mesenchymal-epithelial transition factor savolitinib |
| url | http://www.zlfzyj.com/en/article/doi/10.3971/j.issn.1000-8578.2024.23.0909 |
| work_keys_str_mv | AT zhongcheng therapeuticeffectofsavolitinibinpatientswithstageiiiivnonsmallcelllungcancer AT zhangyang therapeuticeffectofsavolitinibinpatientswithstageiiiivnonsmallcelllungcancer AT chuziang therapeuticeffectofsavolitinibinpatientswithstageiiiivnonsmallcelllungcancer AT qianhong therapeuticeffectofsavolitinibinpatientswithstageiiiivnonsmallcelllungcancer |